AcroMetrix COVID-19 RNA Control is offered at two different concentrations, a low positive control and an ultra-low positive control
Thermo Fisher previous headquarters in Waltham, Massachusetts. (Credit: Coolcaesar /Wikipedia.)
US-based medical technology firm Thermo Fisher Scientific has developed new AcroMetrix Coronavirus 2019 (COVID-19) RNA Control for COVID-19 molecular diagnostic tests.
The new AcroMetrix RNA control has been designed and developed to enable the labs to validate and monitor COVID-19 molecular diagnostic tests, to combat the recent coronavirus outbreak.
Thermo Fisher speciality diagnostics business senior vice president and president Gianluca Pettiti said: “Our team is committed to providing innovative solutions to support our customers with better diagnostic tools. The AcroMetrix Coronavirus 2019 (COVID-19) RNA Control is a positive control to aid in validating and monitoring COVID-19 diagnostic tests.”
Thermo Fisher has rolled out new AcroMetrix as Research Use Only (RUO) product
The company said that its AcroMetrix COVID-19 RNA Control is offered at two different concentrations, a low positive control and an ultra-low positive control, under the US FDA guidelines.
Also, the new RNA control is prepared by formulating synthetic RNA transcripts containing unique N, S, E and Orf1ab regions of SARS-CoV-2 genome into a proprietary buffer. The RNA can be readily used for reverse transcription, PCR amplification and detection.
The kit comprises two vials of SARS-CoV-2 specific RNA, facilitating low positive and ultra-low positive in Polymerase Chain Reaction (PCR) based Coronavirus 2019 (COVID-19) nucleic acid testing methods.
Thermo Fisher has rolled out the new AcroMetrix COVID-19 RNA Control across the world as a Research Use Only (RUO) product and is not available for clinical use.
Furthermore, the company has created an online resource to provide the latest information about the COVID-19 pandemic, including the availability of its diagnostic test kits.